| Title : Acetylcholinesterase inhibition increases in vivo N-(2-[18F]fluoroethyl)-4-piperidyl benzilate binding to muscarinic acetylcholine receptors - Skaddan_2001_J.Cereb.Blood.Flow.Metab_21_144 |
| Author(s) : Skaddan MB , Kilbourn MR , Snyder SE , Sherman PS |
| Ref : Journal of Cerebral Blood Flow & Metabolism , 21 :144 , 2001 |
| Abstract : Although the inhibition of acetylcholinesterase remains the primary treatment of Alzheimer's disease, little is known of the results of increased acetylcholine levels on muscarinic receptor occupancy or function. Using N-(2-[18F]fluoroethyl)-4-piperidyl benzilate ([18F]FEPB), a moderate affinity (Ki = 1.7 nmol/L) nonsubtype-selective muscarinic receptor antagonist, the authors examined the sensitivity of equilibrium in vivo radioligand binding in rat brain with changes in endogenous acetylcholine levels produced by treatments with acetylcholinesterase inhibitors. Phenserine administration 30 minutes before resulted in a dose-dependent into muscarinic cholinergic receptors, reaching a maximum increase of 90% in the striatum at a dose of 5 mg/kg intraperitoneally. Constant infusion of physostigmine at a dosage of 250 microg/kg/min produced an identical increase in radioligand binding. This agonist-induced increase of in vivo mAChR radioligand binding offers a new method for monitoring of the efficacy of acetylcholinesterase inhibitors or other drugs to enhance acetylcholine actions at the muscarinic receptors. |
| ESTHER : Skaddan_2001_J.Cereb.Blood.Flow.Metab_21_144 |
| PubMedSearch : Skaddan_2001_J.Cereb.Blood.Flow.Metab_21_144 |
| PubMedID: 11176279 |
Skaddan MB, Kilbourn MR, Snyder SE, Sherman PS (2001)
Acetylcholinesterase inhibition increases in vivo N-(2-[18F]fluoroethyl)-4-piperidyl benzilate binding to muscarinic acetylcholine receptors
Journal of Cerebral Blood Flow & Metabolism
21 :144
Skaddan MB, Kilbourn MR, Snyder SE, Sherman PS (2001)
Journal of Cerebral Blood Flow & Metabolism
21 :144